Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Iron Overload

• NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
• Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients
• Safety of SP-420 in the Treatment of Transfusional Iron Overload
• Long-term Clinical Study of CN128 in Thalassemia Patients
• Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
• The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
• Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissue Iron Overload in Lower Risk MDS
• Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload
• SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias
• Safety and Efficacy of Early Treatment With Deferiprone in Infants and Young Children
• A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis
• A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Patients With Transfusion-Dependent Beta Thalassemia
• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis
• Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation
• Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia
• Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients
• Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients
• Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload
• Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia
• Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
• Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
• Treatment of Iron Overload Requiring Chelation Therapy
• Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
• Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
• Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients
• Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
• Pharmacokinetic Study of Deferiprone in Paediatric Patients
• Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia
• Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)
• Post Hematopoietic Stem Cell Transplantation
• Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy
• Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia
• Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload
• Iron Metabolism in Small Pre Term Newborns
• Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
• Efficacy and Safety of Desferal Versus Osveral in Transfusional Iron Overload
• Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload
• Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron Overload
• Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study
• Safety and Efficacy of Oral Deferasirox in Patients With Porphyria Cutanea Tarda
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron Overload
• This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.
• Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload
• Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
• Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
• A Protocol to Allow Treatment With ICL670 for Patients With or at Risk of Life-threatening Complications of Transfusional Iron Overload Who Are Unable to Tolerate Other Iron Chelators Because of Documented Severe Toxicity
• Safety and Pharmacokinetic Study of Escalating Multiple Doses of an Iron Chelator in Patients With Iron Overload
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension Study
• Therapeutic Effects of Silymarin in Patients With B-thalassemia Major
• Clinical Importance of Treating Iron Overload in Sickle Cell Disease
• Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)
• Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study
• Intensive Combined Chelation Therapy for Iron-Induced Cardiac Disease in Patients With Thalassemia Major
• Oral Nifedipine to Treat Iron Overload
• Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
• Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation
• Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron Overload
• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
• Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron Overload
• Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
• Safety and Efficacy of Ferriprox™ (Deferiprone) Oral Solution in Iron Overloaded Pediatric Patients
• Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
• ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
• Evaluation the Effect of Exjade on Oxidative Stress in Low Risk Myelodysplastic Syndrome Patients With Iron Over Load
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis
• A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
• Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron Overload
• Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
• Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease
• Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
• A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
• An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
• Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia
• Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic Anemias
• Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
• Combination Iron Chelation Therapy
• Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)
• Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
• Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone